FCA 2019: Key Issues Include DOJ Dismissal, Statute Of Limitations
Court rulings related to the False Claims Act (FCA) this year focused on whistleblower rules and further clarifying the theory of liability, given in the Supreme Court’s 2016 Escobar decision, Gibson Dunn health-care attorneys say.
You may also be interested in...
Avalign Technologies is paying $9.5m to settle fraud charges. The company and its Instrumed International subsidiary sold unapproved devices that they falsely claimed held pre-amendment status.
The US Supreme Court announced Monday that it won’t hear a much-watched case that could have limited the government’s ability to bring False Claims Act cases if it knew of the alleged misconduct. Two drug-world patent cases were also declined.
Industry groups praised newly enacted opioid-control legislation Oct. 24. The legislation will put more attention on existing medtech alternatives to addictive opioids and support research on new devices. Industry was positive about the new law, despite its expansion of sunshine reporting requirements that they oppose.